Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
about
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
P2860
Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@en
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@nl
type
label
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@en
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@nl
prefLabel
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@en
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@nl
P2093
P2860
P356
P1476
Safety and efficacy of guselku ...... trolled, ascending-dose study.
@en
P2093
P2860
P356
10.1111/BJD.16236
P407
P50
P577
2017-12-09T00:00:00Z